Ergoteles’s BioCryst Pharmaceuticals BCRX Stock Holding History

Ergoteles’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-78,216	Closed	-$898K	–	1268
2022 Q4	$898K	Sell	78,216 -13,031	-14%	-$163K	0.03%	494
2022 Q3	$1.15M	Buy	+91,247	New	+$1.17M	0.04%	433
2021 Q3	–	Sell	-32,062	Closed	-$507K	–	1222
2021 Q2	$507K	Buy	+32,062	New	+$436K	0.01%	803

Other funds holding BCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Ergoteles's BCRX Position: Q1 2023 in Review

Ergoteles sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2023, closing a stake of 78,216 shares — an estimated $898K sold.

Ergoteles first reported a position in BCRX in Q2 2021 and held it in 3 quarters. The position peaked at $1.15M in Q3 2022. 241 funds tracked by Wall St. Rank hold BCRX as of Q1 2023.

Ergoteles reported no remaining BioCryst Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Ergoteles sold 78,216 BioCryst Pharmaceuticals shares in Q1 2023, an estimated $898K.
Ergoteles first reported a position in BioCryst Pharmaceuticals in Q2 2021 and held it in 3 quarters.
Ergoteles's BioCryst Pharmaceuticals position peaked at $1.15M in Q3 2022.
241 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.